With Mild and More Severe Intellectual Disabilities Referred to a Dual Diagnosis Service. Abstract. Authors

Similar documents
S. Deb, M.Thomas & C. Bright. Abstract

Dr Keith Ganasen Department of Psychiatry UCT

Abstract. Methods. Participants. Authors. Alexander Milovanov, 1 Melissa Paquette-Smith, 1 Yona Lunsky, 1 Jonathan Weiss 2. Correspondence.

Referral trends in mental health services for adults with intellectual disability and autism spectrum disorders

Prescribing for people with a personality disorder. POMH-UK QIP 12b

Research in Autism Spectrum Disorders

General Hospital Psychiatry 23 (2001)

Because of the many changes in

NCI Data Brief. ISSUE 6 December 2012

Professor Tony Holland, Department of Psychiatry, University of Cambridge

Psychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson

Recent publications in the Psychiatry of Intellectual Disability. March 2009.

Adult Mental Health Services applicable to Members in the State of Connecticut subject to state law SB1160

CLE ABSTRACT INTRODUCTION SUBJECTS AND METHODS. Standards (National) JPPS 2011; 8(2): AUDIT

The Relevance of an Employee Assistance Program to the Treatment of Workplace Depression

Interventions for challenging behaviour in intellectual disability

Epidemiology of mental health problems in adults with learning disability: an update

Supplementary Online Content

Unrecognized Medical Concern as Cause of Psychiatric Disorder and Challenging Behaviour in Developmental Disability: A Case Study.

TITLE: Practice parameters for the assessment and treatment of children and adolescents with posttraumatic stress disorder.

Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand

Psychotropic Medication Use by Adults with Intellectual Disabilities Living in Community Settings. Tanya Christa Sokolowski, H. BSc.

Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative

The age related prevalence of aggression and selfinjury in persons with an intellectual disability: A review. Davies, L. and Oliver, C.

Clinical Guidelines for the Pharmacologic Treatment of Schizophrenia

Prescribing antipsychotics for children and adolescents

CLP PSYCHOPATHOLOGY Course Syllabus Fall 1999

This version was downloaded from Northumbria Research Link:

A critical Examination of the Effectiveness of Pharmacological Intervention for Challenging Behaviour in Individuals with Intellectual Disabilities.

DESIGN TYPE AND LEVEL OF EVIDENCE: Randomized controlled trial, Level I

ESSENTIAL SHARED CAR E AGREEMENT FOR

MICHAEL PRITCHARD. most of the high figures for psychiatric morbidity. assuming that a diagnosis of psychiatric disorder has

Understanding Mental Health Preadmission Screening and Resident Review (PASRR) and Form Valerie Krueger Mental Health PASRR Specialist

FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality

Table 1 Results of the 12-item General Health Questionnaire among caregivers who were or were not evacuated Not evacuated (N=46)

Bock Associates 221 West 2 nd Street, Suite 607 Little Rock, AR 72201

Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia

Community Services - Eligibility

PHARMACOLOGICAL THERAPY OF AUTISM SPECTRUM DISORDERS IN THE CLINICAL PRACTICE

Psychotropics in Learning Disabilities: Systematic reviews. Professor Shoumitro Deb FRCPsych, MD University of Birmingham

Ross, E. & Oliver, C.

Dr. Meldon Kahan. Women s College Hospital. with PIA LAW

Alberta Alcohol and Drug Abuse Commission. POSITION ON ADDICTION AND MENTAL HEALTH February 2007

Relationship Between Mental Health Problems and Challenging Behaviour in People with Intellectual Disabilities

Dr Jane McCarthy Consultant Psychiatrist, East London NHS Foundation Trust & Visiting Senior Lecturer, Department of Forensic & Neurodevelopmental

Benzodiazepines: risks, benefits or dependence

Use of antipsychotic medication in people with a learning disability

Psychotropic Medication. Including Role of Gradual Dose Reductions

CALIFORNIA COUNTIES TREATMENT RECORD REQUIREMENTS

Prescribing medications for people with a personality disorder A service evaluation of a community mental health team

Psychotropic Medication

Diagnosing Psychological Disorders

Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia

German Journal of Psychiatry 2000; 3

6/22/2012. Co-morbidity - when two or more conditions occur together. The two conditions may or may not be causally related.

MODEL PSYCHOPHARMACOLOGY CURRICULUM

CERTIFICATION EXAMINATION IN CHILD AND ADOLESCENT PSYCHIATRY Content Blueprint (October 17, 2018)

Predicting Change in Emotional and Behavioural Problems during Inpatient Treatment in Clients with Mild Intellectual Disability

GOALS FOR THE PSCYHIATRY CLERKSHIP

NOTE: ADVANTAGES TO COMPLETING THE LEVEL I ONLINE AT

Clozapine Use In Personality Disorder and Intellectual Disability

Antidepressant does not relieve repetitive behaviors

CERTIFICATION EXAMINATION IN CHILD AND ADOLESCENT PSYCHIATRY Content Blueprint (October 26, 2015)

Primary Care: Referring to Psychiatry

Psychiatry CPT Coding Changes for Presented by Richard Morgenstern, M.D. Clinical Director, ICANotes

Deposited on: 14 July 2009

MJP Online Early

Assertive Community Treatment Team

NBRHC Regional Programs

Establishing the Link: Assessment and Intervention of Children and Adults October 23, 2018

Pediatric Psychopharmacology

Behavioral Health Treatment in a Primary Care Setting

Review: Psychosocial assessment and theories of development from N141 and Psych 101

Improving Standards for Prescribing Psychotropic Medications in People with Intellectual and Developmental Disabilities

Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009

Mental Health & Your Teen Tools, Strategies & Resources

METHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC

qwertyuiopasdfghjklzxcvbnmqwertyui opasdfghjklzxcvbnmqwertyuiopasdfgh jklzxcvbnmqwertyuiopasdfghjklzxcvb nmqwertyuiopasdfghjklzxcvbnmqwer

Survey of medication for detained patients with a learning disability

Research Journal of Pharmaceutical, Biological and Chemical Sciences

4/28/2014. Initial Psychiatric Diagnostic Interview. Psychiatry and ID The Diagnostic Interview. Assessment Challenges: Improving Diagnosis and DSM-V

EARLY ONSET SCHIZOPHRENIA

ACUTE INPATIENT TREATMENT

The age related prevalence of aggression and selfinjury in persons with an intellectual disability: A review Davies, Louise; Oliver, Christopher

Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care

The contribution of ABA and psychiatry to the emerging model of positive behaviour support

MEDICATION USE IN ADULTS WITH ID/DD LIVING IN COMMUNITY HOMES AND STATE EFFORTS TO REDUCE OVERUSE

Demystifying DSM 5 Diagnosis

American Board of Psychiatry and Neurology, Inc. Geriatric Psychiatry Core Competencies Outline

v1.4 Reformatted (content numbered) 28/06/12 v1.3 Updated with content identified during Stage 1 blueprinting 23/04/12

Bock Associates 221 West 2 nd Street, Suite 607 Little Rock, AR 72201

A cross sectional study on prevalence and pattern of personality disorders in psychiatric inpatients of a tertiary care hospital

Psychotropic drug use in settings for people with intellectual disabilities

Cardiac Patients Psychosocial Needs. Cardiac Patients Psychosocial Needs

Manual of Clinical Psychopharmacology

Acute Stabilization In A Trauma Program: A Pilot Study. Colin A. Ross, MD. Sean Burns, MA, LLP

Professor Tony Holland, Department of Psychiatry, University of Cambridge

Bipolar disorder in children and young people on the autism spectrum

ABNORMAL PSYCHOLOGY. Psychological Disorders. Fast Track Chapter 11 (Bernstein Chapter 15)

New Jersey Department of Children and Families Policy Manual. Date: Chapter: A Health Services Subchapter: 1 Health Services

Transcription:

brief report: Comparison of Clients With Mild and More Severe Intellectual Disabilities Referred to a Dual Diagnosis Service Abstract Authors Jonny Elserafi, 1,2 Stacy E. White, 1 Yona Lunsky 1,2 1 Dual Diagnosis Program, Centre for Addiction and Mental Health Toronto, ON 2 University of Toronto, Toronto, ON Correspondence jonny.elserafi@utoronto.ca Keywords intellectual disability, dual diagnosis Among those with a dual diagnosis, clinical profiles may differ by functioning level (mild versus severe intellectual disability). Few studies have examined these differences. This study examined differences in rates of primary diagnosis, prescribed medication, risk classification for problem behaviours, and demo graphic variables between individuals with mild and more severe intellectual disability (ID). Schizophrenia was more common in adults with mild ID and individuals with moder ate to severe ID were more likely to be classified as presenting with significant disruptive, destructive or aggressive behaviour. The two groups displayed similar psychotropic medication profiles. Possible implications of these results are discussed. The prevalence of mental illness is greater in those with intellectual disability (ID) relative to the general population (Pyles et al., 1997), and there has been increasing recognition of the need for specialized clinical services to support individuals with ID and mental health issues. Within this population, both the prevalence of mental health concerns and approaches to respond to such concerns may vary with cognitive ability. For instance, there have been conflicting reports on the prevalence of mental illness in individuals with more mild disability relative to those with more severe disability. Reiss et al. found no difference in overall prevalence of psychiatric symptomatology, while Holden et al. found mental illness to be more prevalent in participants with moderate ID than in people with severe and profound ID (Holden & Gitlesen, 2004; Reiss, 1988). In addition, it is complicated to diagnose psy chotic disorders in individuals with more se vere disabilities (Reid, 1993). In general, the treatments for individuals with more severe disabilities require more caregiver involvement than may be the case for those with more mild disabilities. However, few studies have compared the clinical profiles of these groups, even though a better understanding of their respective profiles could assist clinicians in better meeting their needs. In the present study, the relationships be tween psychiatric symptomatology and other variables of interest were examined in individuals with mild versus more severe ID. Demographic variables, history of medication, and levels of risks for challenging behaviours were considered along with psychiatric diagnoses in a sample of 103 clients from the Dual Diagnosis Program at the Centre for Addiction and Mental

Comparison of Clients Based on ID Severity 95 Health. It was found that schizophrenia was more common in the mild group and that both groups exhibited challenging behaviours. The findings from this study add to the literature of psychiatric symptomatology and relationship with other variables of interest in individuals with ID. Participants Method The sample was composed of 103 outpatient and inpatient clients receiving services be tween 2006 and 2008 from the Dual Diag nosis Program at the Centre for Addiction and Mental Health, a tertiary level service for individuals with a dual diagnosis from across Toronto and Peel regions. At the time of referral, 11 individuals were diagnosed with borderline intellectual functioning, 46 with mild ID, 3 with borderline/ mild ID and 26 with moderate and 17 with severe ID. For these analyses, clients were divided into two groups (borderline/mild and moderate/severe) based on the level of disability recorded in their medical chart. Measures In addition to demographic data collected upon referral to the program, clients were also classified as mild risk, major risk, or no risk for a range of challenging behaviours, based on caregiver ratings. A history of psychia tric diagnoses and medication information was also included in their charts. Procedure A retrospective chart review was conducted to collect demographic, diagnostic, behavioural and medication information for inpatients and outpatients of the Dual Diagnosis Program at CAMH between 2006 and 2008. This study was approved by the Research Ethics Board at the Centre for Addiction and Mental Health. Results Chi square analyses were used to test the signifi cance of differences among the two groups. P-values less than 0.05 were considered significant. Bonferroni corrections were not used. Demographic Variables Demographic information is shown in Table 1. The two groups did not differ significantly with regard to gender (50/50 versus 63/37) or distribution across age categories. The mean age of clients with borderline/mild ID (M = 35.38, SD = 12.07) did not differ significantly from clients with moderate/severe ID (M = 32.77, SD = 12.31) (t = 1.076, p = 0.285). Primary Diagnosis Diagnostic information was available for 53 individuals with borderline/mild ID and 40 individuals with moderate/severe ID and is shown in Table 2. Anxiety, mood, personality and other disorders were grouped together due to a small number of patients within each category. The separate trend in all four of these categories was the same and the combined categories showed no difference between the two groups. Individuals with mild ID were more likely to be diagnosed with schizophrenia than individuals with more severe ID. Individuals with moderate/ severe ID were less likely to have a psychiatric diagnosis at the time of referral to service than individuals with a mild disability. Risk Classification for Problem Behaviours Information regarding risk classification for problem behaviours was available for 20 individuals with borderline/mild ID and 19 individuals with moderate/severe ID and is shown in Table 2. Each of these clients was classified as either mild, major or no risk in three separate categories (disruptive, aggressive, and destructive behaviour) resulting in 60 observations for individuals with borderline/mild ID and 57 observations for individuals with moderate/severe ID. Individuals with moderate/severe ID were more likely than individuals with borderline/mild ID to be classified as major risks for disruptive, destructive or aggressive behaviour according to caregiver report at the time of referral. Individuals with borderline/mild ID were more likely than individuals with moderate/ severe ID individuals to be classified as no risk for disruptive, destructive, or aggressive behaviour. Individuals with moderate/severe ID v.15 n.2

96 Elserafi et a l. Table 1. Differences in demographic variables and primary diagnoses between individuals with mild/ borderline ID and individuals with moderate/severe ID Gender Male Female Age 0 20 21 40 41 60 61+ *Primary Axis I Diagnosis Psychotic disorder Other (Anxiety, mood, personality and other disorders) No Axis I Diagnosis Borderline/ Mild ID n (%) 30 (50.0) 30 (50.0) 6 (10.0) 35 (58.3) 18 (30.0) 1 (1.7) n = 53 16 (30.2) 20 (37.7) 17 (32.1) Moderate/ Severe ID n (%) χ 2 p-value n = 43 27 (62.8) 1.658 0.198 16 (37.2) n = 43 7 (16.3) 28 (65.1) 7 (16.3) 1 (2.3) n = 40 1 (2.5) 14 (35.0) 25 (62.5) 0.895 0.485 2.566 11.699 0.074 8.25 0.344 0.486 0.109 0.001 0.786 0.004 * Primary Axis 1 Diagnosis refers to the individual s primary mental health diagnosis, based on categories in the Diagnostic and Statistical Manual of Mental Disorders (APA, 1994). Table 2. Risk classification for disruptive, destructive, or aggressive behaviour and prescribed medication for individuals with Risk classification Major Risk Mild Risk No Risk Medication Anti-Depressants Anxiolytics Anti-Psychotics Other (Mood-Stabilizers, Stimulants, Anti- Convulsants, and Betablockers) Borderline/ Mild ID n (%) 16 (26.7) 21 (35.0) 23 (38.3) n = 48 16 (33.3) 25 (52.1) 37 (77.1) 18 (37.5) Moderate/ Severe ID n (%) χ 2 p-value n = 57 28 (49.1) 20 (35.1) 9 (15.8) n = 40 12 (30.0) 19 (47.5) 24 (60.0) 19 (35.8) 6.282 0.000 7.477 0.162 0.183 2.994 0.895 0.012 0.993 0.006 0.683 0.669 0.084 0.344 JoDD

Comparison of Clients Based on ID Severity 97 and individuals with borderline/mild ID were equally likely to be classified as mild risks for disruptive, destructive, or aggressive behaviour. Prescribed Medication Medication information was available for 48 individuals with borderline/mild ID and 40 individuals with moderate/severe ID and is shown in Table 2. Individuals with moderate/ severe ID and individuals with borderline/mild ID were equally likely to be prescribed antidepressants, anxiolytics, and other medications (mood stabilizers, stimulants, anti-consultants, and beta-blockers). There was a non-significant trend for more anti-psychotics prescribed to individuals with borderline or mild ID relative to individuals with moderate/severe ID. Discussion This study compared individuals with mild ID to individuals with more severe ID and found significant differences between these two groups. Individuals with more severe ID were less likely to have a psychiatric diagnosis at the time of referral to the program when compared to individuals with mild ID. These results concur with Holden and Gitlesen (2004), who found that psychiatric symptomology decreases with severity of ID. In addition, this study found that individuals with more severe ID were more likely to be classified as risks for problem behaviours than individuals with mild ID. This is the same pattern reported by Moss and colleagues for self-injurious behaviour (2000). It has been hypothesized that problem behaviours occur with great frequency among individuals with ID because of a frustration with the inability to communicate with others, among other reasons (Carr et al., 1996). This might explain why individuals with moderate or severe ID were more likely to be classified as risks for problem behaviours, as their inability to communicate is greater than that of individuals with borderline or mild ID. Regardless of the cause of these problem behaviours, the individuals with moderate or severe ID in this study are experiencing distress worthy of attention from a mental health team, yet their symptoms may not fall under the classification of a traditional disorder. It may be that internal symptoms of disorders (particularly psychotic disorders) are more difficult to diagnose in individuals with moderate or severe ID. Holden and Gitlesen (2004) have suggested that standard psychiatric examinations are less useful for individuals with severe ID. Alternatively, this could be a case of diagnostic overshadowing as the problem behaviours observed in individuals with moderate or severe ID may be attributed to the severity of ID, and an additional diagnosis may not be made (Mason & Scior, 2004). This study also found that individuals with more severe ID are just as likely as individuals with mild ID to be prescribed antidepressants, antipsychotics and anxiolytics, despite being less likely to be given an additional diagnosis beyond ID. It is possible that psychiatrists are prescribing medication based on problem behaviours observed rather than psychiatric diagnoses in this group. There is limited evidence for the efficacy of medications for behavioural problems. For instance, Tyrer and colleagues found that anti-psychotics had no greater effect than placebos in reducing aggressive behaviour in individuals with ID (2008). It is important that when individuals with more severe disability are prescribed psychotropic medications for behaviour as opposed to an underlying psychiatric condition, that behaviour monitoring is taking place so that one can objectively determine whether the medication has the hypothesized benefit. A major limitation of this study is the small sample size. These analyses should be replicated with a larger sample, since the current findings include non-significant trends that are hindered by the low power of the analysis. Clinical services like the Dual Diagnosis Program can meet the needs of individuals across the range of cognitive functioning. Therefore, in designing services, service providers should recognize that individuals with differing levels of ID may have unique needs. For example, restricting a service to individuals with a formal psychiatric diagnosis would prevent individuals with more severe disabilities from accessing services, even though they have significant behavioural issues, similar medication profiles and a clear need for such services. Future research should explore exactly how the psychiatric symptoms in the two groups differ and why these symptoms are leading to similar rates of psychotropic medication use between the two groups. v.15 n.2

98 Elserafi et a l. References American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders (4 th ed). Washington, DC: American Psychiatric Publishing, Inc. Carr, E. G., Reeve, C. E., & Magito- McLaughlin, D. (1996). Contextual influences on problem behaviour in people with developmental disabilities. In L. K. Koegel, R. L. Koegel, & G. Dunlap (Eds.), Positive behavioral support: Including people with difficult behavior in the community (pp. 403 423). Baltimore: Paul H. Brooks Publishing Co., Inc. Holden, B., & Gitlesen, J. P. (2004). The association between severity of intellectual disability and psychiatric symptomatology. Journal of Intellectual Disability Research, 48, 556 562. Mason, J., & Scior, K. (2004). Diagnostic overshadowing amongst clinicians working with people with intellectual disabilities in the UK. Journal of Applied Research in Intellectual Disabilities, 17(2), 85 90. Moss S., Emerson E., Kiernan C., Turner S., Hatton S., & Alborz A. (2000). Psychiatric symptoms in adults with learning disability and challenging behaviour. British Journal of Psychiatry, 177, 452 456. Pyles, D. A. M., Muniz, K., Cade, A., & Silva, R. (1997). A behavioral diagnostic paradigm for integrating behavior-analytic and psychopharmacological interventions for people with a dual diagnosis. Research in Developmental Disabilities, 18, 185 214. Reid A. (1993) Schizophrenic and paranoid symptoms in persons with mental retardation: assessment and diagnosis. In R. J. Fletcher & A. Dosen (Eds.), Mental health aspects of mental retardation (pp. 98 110). New York: Lexington Books. Reiss, S. (1988) The development of a screening measure for psychopathology in people with mental retardation. In E. Dibble & D.B. Gray (Eds.), Assessment of behavior problems in persons with mental retardation living in the community (pp. 107 118). Washington DC: National Institutes of Health. Tyrer, P., Oliver-Africano, P. C., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., et al. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behavior in patients with intellectual disability: A randomized controlled trial. Lancet, 371, 57 63. JoDD